13F Holdings
中文EN

MNOV MEDICINOVA INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1226616 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.2%
TTM EPS YoY16.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,232.2%
Net margin-1,127.0%
FCF margin-1,047.7%
EBITDA margin-1,230.3%

Returns

ROE-24.8%
ROA-22.7%
ROIC (approx.)-78.4%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio8.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$409,657—$1.00M—$4.04M
R&D expense$6.70M$6.80M$5.30M$8.70M$8.10M
SG&A expense$6.16M$5.48M$5.24M$5.48M$5.72M
Operating income-$13.28M-$12.68M-$9.90M-$14.63M-$10.22M
Pretax income-$11.99M-$11.04M-$8.57M-$14.07M-$10.13M
Income tax$5,994$5,537$3,047$2,822$2,568
Net income-$12.00M-$11.05M-$8.57M-$14.07M-$10.13M
EBITDA-$13.26M-$12.65M-$9.88M-$14.61M-$10.19M
EPS (basic)-0.24-0.23-0.17-0.29-0.21
EPS (diluted)-0.24-0.23-0.17-0.29-0.21
Weighted avg. shares (diluted)49.06M49.05M49.05M49.05M48.60M
Balance sheet
Cash & equivalents$30.81M$40.36M$51.00M$18.51M$71.43M
Short-term investments———$39.98M—
Receivables$0$0———
Current assets$30.99M$41.07M$51.17M$58.99M$72.01M
PP&E, net$8,340$25,507$45,800$45,269$57,565
Goodwill$9.60M$9.60M$9.60M$9.60M$9.60M
Total assets$45.60M$55.88M$66.27M$74.15M$87.41M
Current liabilities$3.80M$2.96M$3.28M$3.19M$2.83M
Total liabilities$4.02M$3.37M$3.89M$3.91M$3.73M
Shareholders' equity$41.59M$52.50M$62.38M$70.24M$83.68M
Shares outstanding49.22M49.05M49.05M49.05M49.04M
Cash flow statement
Operating cash flow-$9.81M-$10.64M-$7.43M-$12.91M-$9.38M
Capital expenditure$2,899$895$21,299$5,010$28,732
Free cash flow-$9.81M-$10.64M-$7.45M-$12.92M-$9.41M
Investing cash flow-$2,899-$697$39.91M-$40.01M-$28,732
Financing cash flow$244,018$0—$7,920$20.78M
Depreciation & amortization$20,099$21,077$20,295$17,707$26,149
Stock-based compensation$829,095$1.19M$710,710$642,522$1.72M

Free plan shows the latest 5 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.